Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Centre, a national research platform led by Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

which contains medical records for more than 50 million people across the UK. Diagnosis codes were used to identify patients at least 40 years of age with physician-diagnosed COPD from mid-September ...

2 Division of Pulmonary and Critical Care, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon The author has no relevant affiliations or financial ...

a pulmonologist at Dartmouth Health’s Dartmouth Hitchcock Medical Center, said in a news release from the university. COPD is a chronic lung disease that makes it increasingly difficult for sufferers ...

and the Collins Medical Trust. Source Reference: Stubblefield WB, et al "Factors in initial anticoagulation choice in hospitalized patients with pulmonary embolism" JAMA Netw Open 2025 ...

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...